Skip to main content

Table 3 Treatment characteristics (n = 94)

From: From IB2 to IIIB locally advanced cervical cancers: report of a ten-year experience

Characteristics Whole set of patients (n = 94) Complete CCRT (n = 41) Incomplete CCRT (n = 53) p-value
Pelvic external radiation therapy, n (%) 94 (100) 41 (100) 53 (100) NS
 Total dose, median (IQR) 46 (46–48) 46 (46–48) 46 (46–48) NS
 Total dose boost, median (IQR) 55 (54–56) 56 (54–56) 56 (54–57) NS
 Fractions, median (IQR) 23 (23–25) 23 (23–25) 23 (23–25) NS
Para aortic external radiation therapy, n (%) 3 (3.2) 1 (2.4) 2 (3.8) NS
Radiotherapy technique     
 3D–CRT, n (%) 57 (60.6) 26 (63.4) 31 (58.5) NS
 IMRT, VMAT, n (%) 37 (39.4) 15 (36.6) 22 (41.5)  
Concurrent chemotherapy, n (%) 81 (86.2) 41 (100) 40 (75.5) < 0.01a
 Number of cycles ≥ 4, n (%) 69 (73.4) 41 (100) 28 (52.8) < 0.01a
 Cisplatin, n (%) 64 (68.1) 34 (82.9) 30 (56.6) < 0.01b
 Carboplatin, n (%) 22 (23.4) 11 (26.8) 11 (20.8) NS
Brachytherapy, n (%) 73 (77.7) 41 (100) 32 (60.4) < 0.01a
 PDR, n (%) 72 (76.6) 40 (97.6) 32 (60.4) < 0.01b
 HDR, n (%) 1 (1.1) 1 (2.4) 0 (0) NS
 Dose (Gy), median (IQR) 25 (24–30) 26 (24–30) 25 (24–30) NS
OTT (days), median (IQR) 56 (50–63) 55 (50–64) 56 (53–62) NS
Surgery, n (%) 77 (81.9) 35 (85.4) 42 (79.2) NS
 CHL, n (%) 55 (58.5) 27 (65.9) 28 (52.8) NS
 CHL and para aortic lymphadenectomy, n (%) 7 (7.4) 5 (12.2) 2 (3.8) NS
 Other, n (%) 15 (16) 2 (4.9) 11 (20.8) < 0.03a
Time between brachytherapy and surgery (days), median (IQR) 42 (36–57) 42 (34–53) 45 (38–57) NS
  1. Lymph node involvement is assessed according to the initial workup
  2. Abbreviations: CCRT Concomitant Chemoradiotherapy, IQR Interquartile Range, 3D–CRT 3D Conformal Radiotherapy, IMRT Intensity Modulated Radiotherapy, VMAT Volumetric Modulated Arc Therapy, PDR Pulsed Dose Rate, HDR High Dose Rate, Gy Gray, OTT Overall Treatment Time, CHL Colpohysterectomy with bilateral adnexectomy and pelvic Lymphadenectomy
  3. aFisher test, bChi square test